These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8472357)

  • 1. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
    Dutton J; Copeland LG; Playfer JR; Roberts NB
    Clin Chem; 1993 Apr; 39(4):629-34. PubMed ID: 8472357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection.
    Tuomainen P; Männistö PT
    Eur J Clin Chem Clin Biochem; 1997 Mar; 35(3):229-35. PubMed ID: 9127745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
    Betto P; Ricciarello G; Giambenedetti M; Lucarelli C; Ruggeri S; Stocchi F
    J Chromatogr; 1988 Dec; 459():341-9. PubMed ID: 3243910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of levodopa and its metabolites with colorimetry of uric acid.
    Bierer DW; Quebbemann AJ
    Clin Chem; 1981 May; 27(5):756-8. PubMed ID: 7226501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine outpatient L-dopa monitoring in elderly patients with Parkinson's disease.
    Copeland LG; Dutton J; Roberts NB; Playfer JR
    Age Ageing; 1994 Mar; 23(2):138-41. PubMed ID: 8023722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method for the determination of gamma-L-glutamyl-L-dihydroxyphenylalanine and its major metabolites L-dihydroxyphenylalanine, dopamine and 3,4-dihydroxyphenylacetic acid by high-performance liquid chromatography with electrochemical detection.
    Cummings J; Matheson LM; Smyth JF
    J Chromatogr; 1990 Jun; 528(1):43-53. PubMed ID: 2117019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
    Bronaugh RL; MacMurtry RJ; Hoehn MM; Rutledge CO
    Biochem Pharmacol; 1975 Jul; 24(13-14):1317-20. PubMed ID: 1096899
    [No Abstract]   [Full Text] [Related]  

  • 10. Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
    Dethy S; Laute MA; Van Blercom N; Damhaut P; Goldman S; Hildebrand J
    Clin Chem; 1997 May; 43(5):740-4. PubMed ID: 9166225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.
    Treseder SA; Jackson M; Jenner P
    Br J Pharmacol; 2000 Apr; 129(7):1355-64. PubMed ID: 10742291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart failure, aging, and renal synthesis of dopamine.
    Ferreira A; Bettencourt P; Pestana M; Correia F; Serrão P; Martins L; Cerqueira-Gomes M; Soares-Da-Silva P
    Am J Kidney Dis; 2001 Sep; 38(3):502-9. PubMed ID: 11532681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
    Algeri S; Ruggieri S; Miranda F; Casacchia M; Morselli PL; Agnoli A
    Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.
    Blandini F; Martignoni E; Pacchetti C; Desideri S; Rivellini D; Nappi G
    J Chromatogr B Biomed Sci Appl; 1997 Oct; 700(1-2):278-82. PubMed ID: 9390741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.